TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
thrombosis prevention
systematic review
meta-analysis
network meta-analysis
Select
graduated compression stockings
mechanical devices for thromboprophylaxis
anticoagulant
antiplatelets drug
antithrombotics
direct antithrombins
direct factor Xa inhibitors
direct oral anticoagulant (DAO)
heparin (UFH or LMWH)
LMWH
pentasaccharide
UFH
abdominal surgery
All type of patient
all type of surgery
arthroscopy
elective hip replacement
elective major knee surgery
general surgery
gynaecological surgery
hip Fracture
medical patients
neurosurgery
orthopaedic surgery
orthopedic surgery
uncoded clinical condition ***
urologic surgery
antivitamins K
direct factor Xa inhibitors
extended prophylaxis
Extended-duration prophylaxis
Footpump as adjunctive therapy
Footpump monotherapy
GCS (adjunctive therapy)
Graduated compression stockings
IPC
IPC adjunctive therapy
IPC monotherapy
LMWH
Low molecular weight heparin
mechanical
NOAC
oral direct thrombin inhibitor
platelet aggregation inhibitors
recombinant hirudin
synthetic oligosaccharide
UFH
unfractionated heparin
candesartan
LMWH
acenocoumarol
apixaban
ardeparin
aspirin
betrixaban
Certoparin
dabigatran
dalteparin
deltaparin
dipyridamol
edoxaban
enoxaparin
fondaparinux
fraxiparin
nadroparin
phenindione
reviparin
rivaroxaban
suloctidil
ticlopidine
tinzaparin
UFH
warfarin
ximelagatran
vs control
vs control or placebo
vs LMWH
vs pentascharide
vs placebo or control
vs placebo or no treatment
vs antiplatelet drugs
vs aspirin
vs Danaparoid
vs Dextran
vs DHE
vs fondaparinux
vs GCS
vs heparin
vs intermittent pneumatic compression
vs IPC
vs Low molecular weight heparin
vs oral anticoagulant
vs UFH
vs Unfractionated heparin
Filter
hide ongoing
show ongoing
hide ongoing
all ROB
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
all results
Show all trials
Show only trial with conclusive result
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
MA
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
Description
Synopsis
Comparison
Treatments
Patients
Characteristics
Method
Risk of bias
References
None
Tools
Indexation
Results
Global trial result
Main results
All results
All result tag
NCT results
Deep vein thrombosis (711)
non-fatal pulmonary embolism (476)
Major bleeding (462)
Bleeding (436)
fatal pulmonary embolism (429)
All cause death (310)
asymptomatic DVT (263)
Symptomatic pulmonary embolism (256)
wound haematoma / infection (243)
Fatal bleeding (203)
Symptomatic venous thromboembolism (DVT, PE) (189)
proximal DVT (173)
total VTE and all-cause mortality (123)
Symptomatic deep-vein thrombosis (107)
transfusion (107)
non pulmonary embolism death (104)
distal DVT (98)
major VTE (fatal and non fatal DVT,PE) (98)
pulmonary embolism (symptomatic and asymptomatic) (77)
major or clinically relevant non-major bleeding (75)
Coronary event (75)
Venous thromboembolism (64)
myocardial infarction (fatal and non fatal) (33)
Minor bleeding (14)
Venous thromboembolism or death (8)
any bleedings (7)
proximal deep-vein thrombosis (6)
net benefit (2)
Options
Numeric
bar chart
forest plot
medians
Trial
Studied trt
Control trt
patients
tags
ROB
Trial result
Deep vein thrombosis
non-fatal pulmonary embolism
anticoagulant
not classified
Borsgtrom, 1965
no treatment
-
acenocoumarol
Hamulyak, 1994
Acenocoumarol
Nadroparin
negative
18%
Samama, 2001
Acenocoumarol
Reviparin
negative
35%
van Geloven, 1977
Acenocoumarol
unfractionated heparin
Low risk of bias
-
apixaban
ADVANCE 3, 2010
NCT
apixaban
enoxaparin
hip surgery
Low risk of bias
suggesting
-68%
-60%
ADVANCE 2, 2010
NCT
apixaban
enoxaparin (europe regimen)
knee surgery
Low risk of bias
suggesting
-40%
APROPOS 2.5mg, 2007
NCT
apixaban
enoxaparin (US regimen)
knee surgery
Low risk of bias
negative
ADVANCE-1, 2008
NCT
apixaban
enoxaparin (US regimen)
knee surgery
Low risk of bias
suggesting
-5%
dabigatran
RE-NOVATE (150mg), 2007
NCT
dabigatran 150mg
enoxaparin
hip surgery
Low risk of bias
negative
-67%
RE-NOVATE (220mg), 2007
NCT
dabigatran 220mg
enoxaparin
hip surgery
Low risk of bias
negative
70%
RE-NOVATE 2
NCT
dabigatran 220mg
enoxaparin
hip surgery
Low risk of bias
negative
RE-MODEL (150mg), 2007
dabigatran 150mg
enoxaparin (europe regimen)
knee surgery
Low risk of bias
negative
∞%
RE-MODEL (220mg), 2007
dabigatran 220mg
enoxaparin (europe regimen)
knee surgery
Low risk of bias
negative
RE-MOBILIZE (150mg), 2008
dabigatran 150mg
enoxaparin (US regimen)
knee surgery
Low risk of bias
negative
-100%
RE-MOBILIZE (220mg), 2008
dabigatran 220mg
enoxaparin (US regimen)
knee surgery
Low risk of bias
negative
edoxaban
STARS J-V
NCT
edoxaban
enoxaparin (short duration)
hip surgery
Low risk of bias
suggesting
phenindione
Eskeland, 1966
Phenindione
no treatment
-
Hamilton, 1970
Phenindione
no treatment
-
rivaroxaban
RECORD 1, 2008
NCT
rivaroxaban
enoxaparin
hip surgery
Low risk of bias
suggesting
-77%
291%
RECORD 3, 2008
NCT
rivaroxaban
enoxaparin (europe regimen)
knee surgery
Low risk of bias
suggesting
-47%
-100%
ODIXa-HIP 10mg, 2006
rivaroxaban
enoxaparin (short duration)
hip surgery
Low risk of bias
suggesting
-58%
RECORD 2, 2008
NCT
rivaroxaban (long duration)
enoxaparin (short duration)
hip surgery
Low risk of bias
suggesting
-80%
-75%
ODIXa-KNEE, 2005
rivaroxaban
enoxaparin (US regimen)
knee surgery
Low risk of bias
negative
RECORD 4, 2009
NCT
rivaroxaban
enoxaparin (US regimen)
knee surgery
Low risk of bias
suggesting
-51%
warfarin
Pinto, 1970
Warfarin
no treatment
-
Hume, 1973
Warfarin
no treatment
-
Morris, 1976
Warfarin
no treatment
-
Powers, 1989
Warfarin
no treatment
-
Myrhe, 1969
Warfarin
placebo
Low risk of bias
-
RD Heparin, 1994
Warfarin
Ardeparin
suggesting
44%
Heit, 1997
Warfarin
Ardeparin
Low risk of bias
suggesting
31%
Powers, 1989
Warfarin
Aspirin
-
Lotke, 1997
Warfarin
Aspirin
-
Francis, 1997
Warfarin
Dalteparin
suggesting
77%
Hull, 2000
Warfarin
Dalteparin
Low risk of bias
suggesting
102%
Gerhart, 1991
Warfarin
Danaparoid
-
van Comp, 1998
Warfarin
Danaparoid
-
Myrhe, 1969
Warfarin
Dextran
Low risk of bias
-
Harris, 1972
Warfarin
Dextran
-
Barber, 1977
Warfarin
Dextran
-
Francis, 1983
Warfarin
Dextran
-
Leclerc, 1996
Warfarin
Enoxaparin
Low risk of bias
suggesting
40%
Colwell, 1999
Warfarin
Enoxaparin
suggesting
407%
Fitzgerald, 2001
Warfarin
Enoxaparin
suggesting
51%
Paiement, 1987
Warfarin
Intermittent pneumatic compression
-
Bailey, 1991
Warfarin
Intermittent pneumatic compression
-
Kaempffe, 1991
Warfarin
Intermittent pneumatic compression
-
Francis, 1992
Warfarin
Intermittent pneumatic compression
-
Hull, 1993
Warfarin
Logiparin
Low risk of bias
suggesting
19%
Hume, 1973
Warfarin
Sudoxicam
-
Hume, 1973
Warfarin
unfractionated heparin
-
Barber, 1977
Warfarin
unfractionated heparin
-
antiplatelets drug
not classified
Veth, 1985
sp
control
Risk of bias
-
Mocris-C , 1977
Flurbiprofen
no treatment
Exploratory
negative
8%
Massachusetts-I , 1981
Hydroxychloroquine
no treatment
Exploratory
negative
-100%
Denver-Il , 1980
dipyridamol + ASA
placebo
Low risk of bias
negative
-86%
-100%
Carter IA, 1971
hydroxychloroquine
placebo
Low risk of bias
-
Carter IB, 1971
hydroxychloroquine
placebo
Low risk of bias
-
Carter II, 1974
hydroxychloroquine
placebo
Low risk of bias
-
New York, 1977
hydroxychloroquine
placebo
Low risk of bias
-
Vermont, 1975
hydroxychloroquine
placebo
Low risk of bias
-
Massachusetts-II, 1976
Hydroxychloroquine
placebo
Exploratory
suggesting
-88%
-100%
Cooke, 1977
Hydroxychloroquine
placebo
Exploratory
negative
-17%
150%
Hume-A, 1977
Hydroxychloroquine
placebo
Exploratory
negative
0%
Stockholm-II, 1981
Hydroxychloroquine
placebo
Exploratory
negative
3%
Danish-A , 1976
Hydroxychloroquine
placebo
Exploratory
negative
-24%
-65%
Danish-B , 1976
Hydroxychloroquine
placebo
Exploratory
suggesting
-60%
∞%
Wood , 1973
RA233
placebo
Exploratory
negative
43%
Athens, 1981
sp
placebo
Low risk of bias
-
aspirin
Clagett, 1975
aspirin
control
Risk of bias
-
Zekert VI, 1982
aspirin
control
Risk of bias
-
Pasteyer, 1977
Aspirin
no treatment
Exploratory
negative
0%
-100%
Rocha, 1986
Aspirin
no treatment
Exploratory
suggesting
-86%
-100%
Stockholm-I, 1975
Aspirin
placebo
Exploratory
negative
68%
Harris-I, 1977
Aspirin
placebo
Low risk of bias
suggesting
-51%
-100%
McKenna-I, 1980
Aspirin
placebo
Exploratory
suggesting
-56%
-63%
Sautter, 1983
Aspirin
placebo
Exploratory
suggesting
-28%
-55%
McBride, 1983
Aspirin
placebo
Exploratory
negative
5%
Zekert-I , 1974
Aspirin
placebo
Exploratory
suggesting
-58%
-66%
Powers , 1976
Aspirin
placebo
Exploratory
suggesting
-11%
-100%
Erfurt-B , 1979
Aspirin
placebo
Exploratory
negative
-20%
PEP hip-fracture, 2000
aspirin
placebo
Low risk of bias
suggesting
-29%
-26%
MRC, 1972
aspirin
placebo
Low risk of bias
negative
25%
Loew DVT, 1974
aspirin
placebo
Low risk of bias
-
Erfurt-A, 1979
aspirin
placebo
Low risk of bias
-
Zekert V, 1980
aspirin
placebo
Low risk of bias
-
Vinazzer I, 1980
aspirin
placebo
Low risk of bias
-
Vinazzer II, 1977
aspirin
placebo
Low risk of bias
-
PEP elective arthroplasty, 2000
aspirin
placebo
Low risk of bias
-
dipyridamol
Chicago, 1982
aspirin + dipyridamol
control
Exploratory
negative
-38%
Parodi I, 1973
dipyridamol + aspirin
control
Exploratory
suggesting
-63%
Parodi II, 1973
dipyridamol + aspirin
control
Risk of bias
-
Zekert-III, 1977
dipyridamol + aspirin
control
Risk of bias
-
Australian I, 1975
dipyridamol + aspirin
control
Risk of bias
-
Australian II, 1976
dipyridamol + aspirin
control
Risk of bias
-
Toulouse I, 1979
dipyridamol + aspirin
control
Risk of bias
-
Harjola DVT, 1982
dipyridamol + aspirin
control
Risk of bias
-
Weiss, 1977
dipyridamol + aspirin
control
Exploratory
-
Lyon-I, 1975
aspirin + dipyridamol
no treatment
Exploratory
suggesting
-88%
Morris-B , 1977
aspirin + dipyridamol
no treatment
Exploratory
negative
-5%
Morris-A , 1977
dipyridamol
no treatment
Exploratory
negative
-6%
Hamburg, 1976
aspirin + dipyridamol
placebo
Exploratory
negative
-61%
Encke-II , 1976
aspirin + dipyridamol
placebo
Exploratory
negative
29%
-26%
Frankfurt, 1981
aspirin + dipyridamol
placebo
Low risk of bias
negative
100%
Encke IA, 1976
dipyridamol + aspirin
placebo
Low risk of bias
-
Encke IB, 1976
dipyridamol + aspirin
placebo
Low risk of bias
-
suloctidil
Turpie, 1985
Suloctidil
placebo
Low risk of bias
-
ticlopidine
Lasierra, 1982
ticlopidine
placebo
Low risk of bias
-
Walker, 1974
ticlopidine
placebo
Low risk of bias
-
McKenna-II , 1983
ticlopidine
placebo
Low risk of bias
negative
100%
-100%
McKenna-II, 1983
Ticlopidine
placebo
Exploratory
negative
-13%
-33%
Lyon-II
Ticlopidine
placebo
Exploratory
negative
-38%
∞%
Gardecki
Ticlopidine
placebo
Exploratory
negative
-12%
-68%
UFH
Morris, 1974
UFH
no treatment
suggesting
-81%
Welin-Berger, 1982
UFH
no treatment
negative
33%
Bergqvist , 1979
UFH
no treatment
suggesting
-29%
38%
VTCSG, 1975
UFH
no treatment
negative
Mannucci , 1976
UFH
no treatment
suggesting
-69%
Dechavanne, 1974
UFH
no treatment
suggesting
-85%
∞%
Dechavanne, 1975
UFH
no treatment
suggesting
-87%
Bergqvist, 1979
UFH
no treatment
suggesting
-35%
Galasko , 1976
UFH
no treatment
suggesting
-64%
Gallus , 1973
UFH
no treatment
suggesting
-73%
Morris , 1977
UFH
no treatment
negative
-25%
Williams , 1978
UFH
placebo
negative
280%
Abraham-Inpijn , 1975
UFH
placebo
negative
-78%
-100%
Hampson, 1974
UFH
placebo
negative
-35%
Moskovitz, 1978
UFH
placebo
suggesting
-62%
174%
Lahnborg, 1980
UFH
placebo
suggesting
-47%
∞%
Xabregas , 1977
UFH
placebo
negative
-100%
Moskovitz, 1978
UFH
placebo
negative
-1%
∞%
Svend-Hansen, 1981
UFH
placebo
suggesting
-46%
antithrombotics
not classified
Veth, 1985
sp
control
Risk of bias
-
Cohen (L8405), 2007
compression stocking group
control (on top fondaparinux)
hip surgery
Risk of bias
negative
SAVE-HIP1, 2012
NCT
semuloparin
enoxaparin
hip surgery
suggesting
-43%
SAVE-KNEE, 2012
NCT
semuloparin
enoxaparin
knee surgery
negative
-13%
SAVE-HIP 2, 2012
NCT
semuloparin
enoxaparin
hip surgery
negative
-23%
EXCLAIM, 2010
NCT
Extended-duration prophylaxis
error
medical patients
Low risk of bias
suggesting
Borsgtrom, 1965
no treatment
-
Mocris-C , 1977
Flurbiprofen
no treatment
Exploratory
negative
8%
Massachusetts-I , 1981
Hydroxychloroquine
no treatment
Exploratory
negative
-100%
Denver-Il , 1980
dipyridamol + ASA
placebo
Low risk of bias
negative
-86%
-100%
Valle , 1988
fluxum
placebo
negative
Massachusetts-II, 1976
Hydroxychloroquine
placebo
Exploratory
suggesting
-88%
-100%
Cooke, 1977
Hydroxychloroquine
placebo
Exploratory
negative
-17%
150%
Hume-A, 1977
Hydroxychloroquine
placebo
Exploratory
negative
0%
Stockholm-II, 1981
Hydroxychloroquine
placebo
Exploratory
negative
3%
Danish-A , 1976
Hydroxychloroquine
placebo
Exploratory
negative
-24%
-65%
Danish-B , 1976
Hydroxychloroquine
placebo
Exploratory
suggesting
-60%
∞%
Carter IA, 1971
hydroxychloroquine
placebo
Low risk of bias
-
Carter IB, 1971
hydroxychloroquine
placebo
Low risk of bias
-
Carter II, 1974
hydroxychloroquine
placebo
Low risk of bias
-
New York, 1977
hydroxychloroquine
placebo
Low risk of bias
-
Vermont, 1975
hydroxychloroquine
placebo
Low risk of bias
-
Dahan, 1986
Pharmuka
placebo
medical patients
Low risk of bias
suggesting
-67%
Wood , 1973
RA233
placebo
Exploratory
negative
43%
Athens, 1981
sp
placebo
Low risk of bias
-
Marlovits, 2007
extended-duration thromboprophylaxis
standard-duration thromboprophylaxis
Risk of bias
suggesting
DRIVE, 2008
NCT
SR123781A
enoxaparin
hip surgery
Low risk of bias
-